UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | August 13, 2024 |
Accession Number: | 0001493152-24-031046 | ||||||
Submission Type: | POS AM | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | August 13, 2024 |
Accession Number: | 0001493152-24-031046 | ||||||
Submission Type: | POS AM | ||||||
|
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/25/2023 | Buy → Neutral | Ladenburg Thalmann |
Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (OTCQB:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the first q
Initiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systemsThe Company is engaged in the process to seek strategic partnerships aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueRecent exercise of certain outstanding warrants provided infusion of $2.7M in gross proceeds to the Company, which extended its cash runway into the fourth quarter of 2024 FORT LAUDERDALE, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes a
Aldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (NASDAQ:MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer. Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical devi
SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)
SC 13G - Motus GI Holdings, Inc. (0001686850) (Subject)
SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)
Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (OTCQB:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the first q
The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueThe Company is actively supporting its existing installed customer base and pipeline opportunities in contracted health systems The Company is advancing its development of Pure-Vu EVS Gastro, designed for Upper GI bleeding procedures, and expects submission to FDA by the end of 2023 FORT LAUDERDALE, Fla., March 31, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and e
Pure-Vu EVS approved for use at 25 hospitals since launch in March 2022, resulting in highest quarterly revenue reported in the Company's historyRecently named a Sole Source Supplier by the Department of Veteran's Affairs, with several VA medical centers executing new contracts for Pure-Vu EVS systems under this designationPresented positive clinical data in three abstracts at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting that further illustrate how Pure-Vu EVS is enabling physicians to significantly improve visualization during colonoscopy procedures across different settings and patient populations FORT LAUDERDALE, Fla., Nov. 14, 2022 (GLOBE NEWSW
EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)
EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)
EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)
4 - Motus GI Holdings, Inc. (0001686850) (Issuer)
4 - Motus GI Holdings, Inc. (0001686850) (Issuer)
4 - Motus GI Holdings, Inc. (0001686850) (Issuer)
Ladenburg Thalmann downgraded Motus GI from Buy to Neutral
- SEC Filing
Gainers Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. The company's market cap stands at $40.7 million. Allarity Therapeutics (NASDAQ:ALLR) stock rose 18.09% to $2.48. The market value of their outstanding shares is at $1.1 million. Galecto (NASDAQ:GLTO) stock increased by 5.58% to $0.72. The company's market cap stands at $19.4 million. Finch Therapeutics Gr (NASDAQ:FNCH) shares increased by 5.28% to $2.19. The company's market cap stands at $3.5 million. CNS Pharma (NASDAQ:CNSP) stock rose 4.97% to $0.26. The market value of their outstanding shares is at $2.7 million. Cormedix (NASDAQ:CRMD) shares rose 4.96% to $6.13. Th
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 500 points on Friday. The Dow traded down 1.37% to 37,934.02 while the NASDAQ fell 1.82% to 16,142.15. The S&P 500 also fell, dropping, 1.61% to 5,115.54. Check This Out: Best Buy, Box And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Utilities shares fell by just 0.7% on Friday. In trading on Friday, materials shares dipped by 2%. Top Headline BlackRock, Inc. (NYSE:BLK) posted stronger-than-expected earnings for its first quarter. Revenue growth of 11% Y/Y to $4.728 billion, beating the consensus of $4.676 billion. Adjusted EPS increased 24% Y/Y to $9.81, be
Aldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (NASDAQ:MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer. Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical devi
FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company's Board of Directors (the "Board"). Mr. Durbin has more than 25 years of executive leadership, finance and clinical development experience, including the execution of over $5 billion in financings and merger transactions. In addition, the Company announced that David Hochman and Darren Sherman, independent members of the Board, have stepped down from the Board due to time requirements of their roles as Chief Executive Offi
Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly created Executive Vice President (EVP) of Corporate Development and Strategy role Andrew Taylor joins as Chief Financial Officer (CFO) with over 20 years of CFO experience with emerging growth companies, the last 15 of which were spent in the medical device sector NEW HOPE, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-rewa